Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
70
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
Filings
Presentations
Events
Refresh
Exchange Announcement •
06 May 2024 16:58
Voluntary Announcement - Application For The Phase 3 Clinical Trial Of Hlx22 (Anti-Human Epidermal Growth Factor Receptor-2 (Her2) Humanized Monoclonal Antibody Injection) In Combination With Trastuzumab And Chemotherapy As The First-Line Treatment Of Her2 Positive Advanced Gastric Cancer Approved By The United States Food And Drug Administration (Fda)
Attachment
Exchange Announcement •
29 Apr 2024 16:30
Voluntary Announcement - 2024 First Quarterly Update
Attachment
Exchange Announcement •
26 Apr 2024 12:20
Inside Information Announcement - Hlx02 (Trastuzumab-Strf, Proprietary Name In The United States: Hercessi) For The Treatment Of Adjuvant Breast Cancer, Metastatic Breast Cancer And Metastatic Gastric Cancer Approved By The United States Food And Drug Administration (Fda)
Attachment
Exchange Announcement •
23 Apr 2024 16:49
Voluntary Announcement - The First Subject Has Been Dosed In A Phase 1 Clinical Study In Healthy Subjects Of Hlx6018 In Mainland China
Attachment
Exchange Announcement •
17 Apr 2024 16:56
Voluntary Announcement - Application For The Clinical Trial Of Hlx53 (Anti-Tigit Fc Fusion Protein) In Combination With Hansizhuang (Serplulimab Injection) And Hanbeitai (Bevacizumab Injection) For The First-Line Treatment Of Locally Advanced Or Metastatic Hepatocellular Carcinoma Was Approved By The National Medical Products Administration
Attachment
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.31.2
x